Literature DB >> 7774630

Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin).

V Ruiz de Souza1, M P Carreno, S V Kaveri, A Ledur, H Sadeghi, J M Cavaillon, M D Kazatchkine, N Haeffner-Cavaillon.   

Abstract

We have investigated the effects of intravenous immunoglobulin (IVIg), a therapeutic preparation of normal human polyspecific IgG, on the synthesis and release of cytokines by peripheral blood monocytes. IVIg was found to selectively induce gene transcription and secretion of interleukin-1 receptor antagonist (IL-1ra) and IL-8 in cultures of normal human monocytes. The addition of IVIg to cultures of purified monocytes induced a dose-dependent secretion of IL-1ra and IL-8 without stimulating the production of IL-1 alpha, IL-1 beta, tumor necrosis factor-alpha or IL-6. The effects of IVIg required both the Fc and F(ab')2 portions of IgG. IVIg-induced production of IL-8 by monocytes was enhanced by lipopolysaccharide (LPS), although LPS inhibited the secretion of IL-1ra, suggesting that IVIg and LPS stimulate distinct intracellular pathways in monocytes. Induction of IL-1ra and IL-8 by IVIg was enhanced in the presence of autologous T lymphocytes. Our observations document the selectivity of the effects of IVIg on the synthesis of cytokines and cytokine antagonists by human monocytes. Induction of IL-1ra and IL-8 by IVIg may contribute to the anti-inflammatory effects of immunoglobulin therapy in patients with autoimmune and systemic inflammatory disorders.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7774630     DOI: 10.1002/eji.1830250521

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  19 in total

1.  Expression of IL-8 in Kawasaki disease.

Authors:  T Asano; S Ogawa
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

Review 2.  Mechanisms of polyclonal hypogammaglobulinaemia in multiple myeloma (MM).

Authors:  M C Kyrtsonis; A Mouzaki; A Maniatis
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

Review 3.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

Review 4.  Clinical uses of intravenous immunoglobulin.

Authors:  S Jolles; W A C Sewell; S A Misbah
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 5.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

Review 6.  Clinical immunology.

Authors:  T E Mollnes; M Harboe
Journal:  BMJ       Date:  1996-06-08

7.  Cytokine responses of human blood monocytes stimulated with Igs.

Authors:  J L Foreback; D G Remick; E Crockett-Torabi; P A Ward
Journal:  Inflammation       Date:  1997-10       Impact factor: 4.092

8.  Administration of intravenous immunoglobulin (IVIG) in vivo--down-regulatory effects on the IL-1 system.

Authors:  P Aukrust; F Müller; M Svenson; I Nordøy; K Bendtzen; S S Frøland
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

9.  Intravenous immunoglobulin and immune response.

Authors:  S V Kaveri; M Lecerf; C Saha; M D Kazatchkine; S Lacroix-Desmazes; J Bayry
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

10.  Intravenous immunoglobulin suppresses the polarization of both classically and alternatively activated macrophages.

Authors:  Chaitrali Saha; Prathap Kothapalli; Veerupaxagouda Patil; Gundallahalli Bayyappa ManjunathaReddy; Srini V Kaveri; Jagadeesh Bayry
Journal:  Hum Vaccin Immunother       Date:  2019-05-07       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.